Docetaxel combined with cisplatin in treatment of anthracycline-resistant advanced breast cancer

Objective: To evaluate the efficacy and safety of Docetaxel combined with cisplatin in treatment of anthracycline-resistant advanced breast cancer.Methods: Docetaxel 75 mg/m² intravenous drip was given at d₁ and cisplatin 25 mg/m² was given intravenous drip at d_1-3.One cycle consisted of 3 weeks.The clinical response was assessed after two cycles.Results: Of the 35 patients,5 achieved complete remission,19 partial remission,6 SD and 5 PD,with a response rate of 68.6%.The main side effects were vomiting,alopecia and neutropenia.Conclusions: Docetaxe and displatin combination is effective on anthracycine-resistant advanced breast cancer with acceptable toxicity.It provides an alternative for patients with advanced breast cancer.